Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21 - Kimmich, Christoph; Terzer, Tobias; Benner, Axel; Hansen, Timon; Carpinteiro, Alexander; Dittrich, Tobias; Veelken, Kaya; Jauch, Anna; Huhn, Stefanie; Basset, Marco; Goldschmidt, Hartmut; Müller-Tidow, Carsten; et al. (American journal of hematology, 2021)
Gesehen am 21.08.2023